» Articles » PMID: 7745467

Proteolysis and Invasiveness of Brain Tumors: Role of Urokinase-type Plasminogen Activator Receptor

Overview
Journal J Neurooncol
Publisher Springer
Date 1994 Jan 1
PMID 7745467
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The cellular receptor for urokinase-type plasminogen activator (uPAR) in glioblastoma cell lines has been identified and found to be similar to the uPAR expressed by other tumor cell lines. Increased levels of uPAR have been found in primary malignant brain tumor tissues, especially highly malignant glioblastoma, and, to a lesser degree, in malignant astrocytomas, suggesting that this receptor might be involved in efficient activation of pro-uPA and confinement of uPA activity on the cell surface of invading brain tumors. The cell surface uPARs in gliomas could constitute an optimum environment for the generation and activity of plasmin, which is known to play a crucial role in the dissolution of the extracellular matrix during tumor cell invasion. In situ hybridization studies have shown that uPAR mRNA is expressed abundantly in tumor cells and is consistently present at the invasive edges of malignant gliomas. These results imply that uPAR is involved in plasmin-catalyzed proteolysis during glioma invasion and that interference with the uPA:uPAR interactions could constitute a novel approach for developing therapeutic strategies to counteract invasion of brain tumors.

Citing Articles

uPAR: An Essential Factor for Tumor Development.

Lv T, Zhao Y, Jiang X, Yuan H, Wang H, Cui X J Cancer. 2021; 12(23):7026-7040.

PMID: 34729105 PMC: 8558663. DOI: 10.7150/jca.62281.


Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.

Rossmeisl J, Hall-Manning K, Robertson J, King J, Davalos R, Debinski W Onco Targets Ther. 2017; 10:2077-2085.

PMID: 28442916 PMC: 5396930. DOI: 10.2147/OTT.S132964.


The role of myosin II in glioma invasion: A mathematical model.

Lee W, Lim S, Kim Y PLoS One. 2017; 12(2):e0171312.

PMID: 28166231 PMC: 5293275. DOI: 10.1371/journal.pone.0171312.


Glioblastoma multiforme: State of the art and future therapeutics.

Wilson T, Karajannis M, Harter D Surg Neurol Int. 2014; 5:64.

PMID: 24991467 PMC: 4078454. DOI: 10.4103/2152-7806.132138.


Diphtheria toxin-based targeted toxin therapy for brain tumors.

Li Y, Vallera D, Hall W J Neurooncol. 2013; 114(2):155-64.

PMID: 23695514 DOI: 10.1007/s11060-013-1157-8.


References
1.
Schwartz B . Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism. J Biol Chem. 1994; 269(11):8319-23. View

2.
Huber R, Carrell R . Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 1989; 28(23):8951-66. DOI: 10.1021/bi00449a001. View

3.
Hollas W, Blasi F, Boyd D . Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 1991; 51(14):3690-5. View

4.
Olson D, Pollanen J, Hoyer-Hansen G, Ronne E, Sakaguchi K, Wun T . Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem. 1992; 267(13):9129-33. View

5.
Quax P, van Muijen G, Lund L, Dano K, Ruiter D, Verheijen J . Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol. 1991; 115(1):191-9. PMC: 2289921. DOI: 10.1083/jcb.115.1.191. View